48±0.15)和(0.09±0.01)μmol/L,RS4;11细胞24、48 h的半数抑制浓度(IC50)分别为(0.91±0.02)和(0.68±0.11)μmol/L。0.5μmol/L MK2206作用于U937细胞及1.0μmol/L MK2206作用于RS4;11细胞24 h、48 h,Annexin V/7-AAD标记的阳性细胞升高,U937细胞组24

h细胞凋亡率为(4.18±0.70)%,48 h细胞凋亡率为(22.53±4.67)%,均高于对照组的(1.35±0.34)%(P
真核延伸因子2激酶(e EF2K)是一种Ca2+/Ca M依赖性蛋白激酶,e EF2是其已知的唯一底物。e EF2K催化e EF2的Thr56位点发生磷酸化,导致降低e EF2与核糖体的结合能力进而抑制肽链延伸。现已发现,e EF2K在多种肿瘤细胞中高表达或高度活化,参与肿瘤进程的调控,因此e EF2K可能是一个潜在的肿瘤治疗靶点。本文就e EF2K的结构、功能、与肿瘤的关系及其抑制剂的研究进展进行综述。
The phosphatidylinositol 3 kinase(PI3K)/AKT pathway is genetically targeted in more pathway PD0325901核磁共振 components and in more tumor types than any other growth factor signaling pathway,and thus is frequently activated as a cancer driver.More importantly,the PI3K/AKT pathway is composed of multiple bifurcating and converging kinase cascades,providing

many potential targets for cancer therapy.Renal cell carcinoma(RCC) is a high-risk and high-mortality cancer that is notoriously resistant to traditional chemotherapies or radiotherapies.The PI3K/AKT pathway is modestly mutated but highly activated in RCC,representing a promising drug target.Indeed,PI3 K pathway inhibitors of the rapalog family are approved for use in RCC.Recent large-scale integrated analyses of a large number of patients have provided a molecular basis for RCC,reiterating 有 the critical role of the PI3K/AKT pathway in this cancer.In this review,we summarize the genetic alterations of the PI3K/AKT pathway in RCC as indicated in the latest large-scale genome sequencing data,as well as treatments for RCC that target the aberrant activated PI3K/AKT pathway.
骨肉瘤(Osteosarcoma)也称成骨肉瘤,是常见的骨原发性恶性肿瘤,具有恶性程度高、侵袭性强、易复发转移等特点[1]。随着新辅助化疗、手术、术后化疗的开展,骨肉瘤5年生存率提高到近80%,但仍有半数以上的患者死于骨肉瘤的转移和复发[2]。有效控制骨肉瘤细胞的转移对延长患者生存期有着深远意义。PI3K/AKT细胞信号转导通路在肿瘤的发生、增殖、迁移、耐药等生物过程中发挥着重要作用。
De

一般 novo neoplasms account for almost 30% of deaths 10 years after liver transplantation and are the most common cause of mortality in patients surviving at least 1 year after transplant. The risk of malignancy is two to four times higher in transplant recipients than in an age- and sex-matched population, and cancer is expected to surpass cardiovascular complications as the primary cause of death in transplanted patients within the next 2 decades. Since exposure to immunosuppression is associated with an increased frequency of developing neoplasm, long-term immunosuppression should be therefore minimized. Promising results in the prevention of hepatocellular carcinoma(HCC) recurrence have been reported with the use of m TOR inhibitors including everolimus and sirolimus and the ongoing open-label prospective randomized controlled SILVER. Study will provide more information on whether sirolimus-containing vs m TOR-inhibitorfree immunosuppression is more efficacious in reducing HCC recurrence.